Treatment.com AI Valuation
Is TREI.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of TREI.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate TREI.F's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TREI.F's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TREI.F?
Key metric: As TREI.F barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is TREI.F's PB Ratio? | |
|---|---|
| PB Ratio | -39.6x |
| Book | -CA$665.18k |
| Market Cap | CA$26.37m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 645.8x |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does TREI.F's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.6x | ||
BFRG Bullfrog AI Holdings | 4.6x | n/a | US$17.6m |
VSEE VSee Health | 4.5x | n/a | US$20.7m |
DRIO DarioHealth | 0.4x | 9.2% | US$24.4m |
AIFF Firefly Neuroscience | 9x | n/a | US$25.3m |
TREI.F Treatment.com AI | n/a | n/a | US$26.4m |
Price-To-Book vs Peers: TREI.F has negative equity and a Price-To-Book Ratio (-39.6x) compared to the peer average (4.6x).
Price to Book Ratio vs Industry
How does TREI.F's PB Ratio compare vs other companies in the US Healthcare Services Industry?
Price-To-Book vs Industry: TREI.F has negative equity and a Price-To-Book Ratio (-39.6x) compared to the US Healthcare Services industry average (1.4x).
Price to Book Ratio vs Fair Ratio
What is TREI.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -39.6x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate TREI.F's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Lantheus Holdings
US$6.0b
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
LNTH
US$87.32
7D
8.0%
1Y
27.8%
Centene
US$29.8b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
CNC
US$60.35
7D
2.8%
1Y
-18.7%
electroCore
US$64.1m
A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
ECOR
US$9.92
7D
-27.1%
1Y
80.4%